Profusa Announces 1-for-25 Reverse Stock Split
Rhea-AI Summary
Profusa (Nasdaq: PFSA) approved a 1-for-25 reverse stock split of its common stock. The split becomes effective at 12:01 a.m. ET on July 7, 2026, with trading on a post-split basis that day under ticker PFSA and new CUSIP 74319X 306.
Every 25 pre-split shares will combine into one share, with par value unchanged at $0.0001. Fractional shares will not be issued; stockholders of record receive cash instead. Outstanding shares will decline from about 13.2 million to approximately 530 thousand, while authorized shares remain 601 million.
Positive
- 1-for-25 reverse stock split effective July 7, 2026
- Outstanding shares reduced from about 13.2M to approximately 530K
Negative
- Authorized common shares remain at 601M after the reverse split
Market reaction: PFSA -28.08% on 1-for-25 reverse stock split
On the day this news was published, PFSA declined 28.08%, reflecting a significant negative market reaction. Argus tracked a trough of -37.0% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $237K from the company's valuation, bringing the market cap to $605,834 at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Stock split Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Reverse stock split | Negative | -36.4% | Announced 1-for-75 reverse split reducing outstanding shares while authorized shares unchanged. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior reverse stock split news for this company coincided with a sharply negative single-day share-price reaction.
Key Terms
reverse stock split financial
cusip financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five (1:25) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on July 7, 2026, and the Company’s common stock will open for trading on The Nasdaq Global Market on July 7, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 306.
As a result of the reverse stock split, every twenty-five (25) shares of the Company’s common stock issued and outstanding prior to the opening of trading on July 7, 2026, will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of
As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 13.2 million shares to approximately 530 thousand shares, and the number of authorized shares of common stock will remain at 601 million shares.
About Profusa
Based in Berkeley, California, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Investor and Media Contacts:
email: info@coreir.com
phone: 1(212) 655-0924
